Drug Trial News

RSS

First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab.

18 Apr 2016

LOXO-101 drug shows efficacy with tumor regression in varied types of genetically defined cancer

A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center.

18 Apr 2016

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI-110) is safe in combination with the chemotherapy drug irinotecan and may overcome resistance to irinotecan in patients with metastatic colorectal cancer.

18 Apr 2016

Radiation plus chemotherapy improves survival of low-grade brain cancer patients

New clinical-trial findings show that patients with a low-grade form of brain cancer who are treated with radiation plus a combination of chemotherapy drugs have better survival than patients treated with radiation alone.

16 Apr 2016

Investigators find tacrolimus to be very effective in reducing ocular symptoms of GVHD

Researchers from Massachusetts Eye and Ear/Harvard Medical School have conducted a clinical trial comparing the safety and efficacy of topical tacrolimus, an immunosuppressive therapy, and topical methylprednisolone, a steroid medication, in patients with ocular graft-versus-host-disease (GVHD) -- a complication associated with allogeneic bone marrow transplants in which the transplanted immune system's cells attack certain parts of the recipient's body, including the cornea and ocular surface.

16 Apr 2016

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie, a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis.

15 Apr 2016

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12).

15 Apr 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme.

15 Apr 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

Binding Site to collarborate in iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial

Binding Site is proud to be a key collaborator with Prof Sigurdur Kristinsson of the University of Iceland in his pivotal MGUS screening study for the forthcoming iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial.

From Binding Site 14 Apr 2016

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients

AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.

13 Apr 2016

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

13 Apr 2016

Novel antibiotics to overcome antibacterial resistance

Small and innovative pharmaceutical companies, with products in early stages of development, presented some of their novel approaches and antimicrobial therapies under development during a dedicated session at the annual congress (ECCMID) of the European Society of Clinical Microbiology and Infectious Diseases(ESCMID) in Amsterdam.

13 Apr 2016

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

AstraZeneca has presented positive data demonstrating the efficacy of the investigational antibiotic, ceftazidime-avibactam (CAZ-AVI), in treating patients with ceftazidime-resistant Gram-negative infections, which are increasingly resistant to most available antibiotics, often precipitating the need for clinicians to reach for agents previously reserved for last-line use.

12 Apr 2016

AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will report new clinical trial and scientific data from their industry-leading lung cancer franchise of marketed and pipeline medicines at the European Lung Cancer Conference in Geneva, Switzerland, 13 -16 April 2016.

11 Apr 2016

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph's Hospital and Medical Center.

7 Apr 2016

Wake Forest Baptist researchers looking for ways to keep older adults on their feet

There's no getting around it: Simply getting around is a major issue for older adults. "People are in nursing homes for two reasons, either they can't think or they can't walk," said Stephen Kritchevsky, Ph.D., director of the Sticht Center on Aging at Wake Forest Baptist Medical Center. North Carolina. "We're working very hard on the thinking part, and the walking part is equally important.

6 Apr 2016

Losmapimod drug fails to meet primary endpoint in clinical trial

Patients taking losmapimod, an anti-inflammatory drug currently being developed, for 12 weeks following a heart attack did not show improvements in the trial's primary endpoint, the rate of cardiovascular death, subsequent heart attack or urgent coronary revascularization, which includes placement of a stent or coronary artery bypass surgery, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

5 Apr 2016

Study elucidates potential benefits of antiarrhythmic drugs for out-of-hospital cardiac arrest patients

Paramedics often give heart rhythm stabilizing drugs to patients who are suffering out-of-hospital cardiac arrest when they fail to regain a stable heart rhythm after electrical shock treatment.

5 Apr 2016

Two common approaches to post-operative AF equally safe, effective

Cleveland Clinic researchers, as part of the Cardiothoracic Surgical Trials Network, have found that two common approaches to post-operative atrial fibrillation - rhythm control and rate control - are equally safe and effective.

5 Apr 2016

Drug Trial News

First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

LOXO-101 drug shows efficacy with tumor regression in varied types of genetically defined cancer

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

Radiation plus chemotherapy improves survival of low-grade brain cancer patients

Investigators find tacrolimus to be very effective in reducing ocular symptoms of GVHD

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

Binding Site to collarborate in iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

Novel antibiotics to overcome antibacterial resistance

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Wake Forest Baptist researchers looking for ways to keep older adults on their feet

Losmapimod drug fails to meet primary endpoint in clinical trial

Study elucidates potential benefits of antiarrhythmic drugs for out-of-hospital cardiac arrest patients

Two common approaches to post-operative AF equally safe, effective

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News